Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Shareholders of Immutep Ltd. (NASDAQ: IMMP) who lost money are urged to act now. On January 30, 2026, Immutep filed a 6-K stating that completion of the...
-
NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- On February 18, 2026, Insulet Corp. (NASDAQ: PODD) CEO Ashley McEvoy told investors on the Q4 2025 earnings call that "our results in the fourth quarter...
-
PRCT: Guided $325.5M, Hid Pricing Headwind -- Levi & Korsinsky, LLP Investigates Procept BioRobotics set aggressive revenue targets while a internal pricing change was already undercutting...
-
NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP is investigating Disc Medicine, Inc. (NASDAQ: IRON) regarding whether the company adequately communicated risks regarding its...
-
NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Ziff Davis, Inc. (NASDAQ: ZD) investors lost more than 10% of their holdings after the Company reported Q4 2025 results that contradicted months of...
-
Surgery Partners (SGRY) Guided for Margin Expansion While Headwinds Mounted -- Levi & Korsinsky, LLP Investigates Levi & Korsinsky, LLP investigates whether Surgery Partners' forward guidance...
-
Levi & Korsinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed
NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Grail, Inc. (NASDAQ: GRAL) lost approximately 50% of its market value after disclosing that the NHS Galleri randomized trial failed to meet its primary...
-
NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Gossamer Bio, Inc. (NASDAQ: GOSS) shareholders suffered significant losses when the Company disclosed that its Phase 3 PROSERA study of seralutinib...
-
NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Avis Budget Group (NASDAQ: CAR) reported adjusted EBITDA growth of 11% for Q4 2025. Under GAAP, the Company posted a net loss of $856 million....
-
NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) lost approximately 70% of their holdings after the FDA issued a Complete Response Letter for...